How much does Epclusa (Sofosbuvir and Velpatasvir Tablets) Cost& price without insurance in China?
Epclusa® is the commercial brand name of Sofosbuvir and Velpatasvir Tablets, an oral fixed-dose combination anti-hepatitis C medicine developed by Gilead Sciences. Sofosbuvir inhibits HCV NS5B polymerase to block viral nucleic acid synthesis, while velpatasvir suppresses NS5A protein to hinder virus assembly, covering all six major HCV genotypes.
Main Indications
Treatment of chronic hepatitis C virus infection in adult patients with or without compensated liver cirrhosis.
Common Side Effects
Common mild adverse reactions: Headache, fatigue, nausea and insomnia.
Laboratory abnormalities: Rare transient mild elevation of liver transaminases.
Severe but manageable risks: Severe bradycardia when co-administered with amiodarone and hypersensitivity reactions.
Approval Status in China
Epclusa® (Sofosbuvir 400mg + Velpatasvir 100mg per tablet, domestic Chinese brand name: Bingtongsha) was officially approved for marketing in China in 2018. It is currently a prescription drug included in China’s Category B medical insurance.
Buy Epclusa (Sofosbuvir and Velpatasvir Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
